All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Impact of Rivaroxaban on Coagulation Function, Inflammatory Factors and Endothelial Function in Coronary Heart Disease after Percutaneous Coronary Intervention

Author(s): Li Ye, Jinglin Cheng* and Xuexiang Li
Department of Internal Medicine, The Second Hospital of Anhui Medical University, Hefei, Anhui Province 230601, China

Correspondence Address:
Jinglin Cheng, Department of Internal Medicine, The Second Hospital of Anhui Medical University, Hefei, Anhui Province 230601, China, E-mail:

To assess how rivaroxaban affects coagulation function, inflammatory factors and endothelial function in individuals who have received percutaneous coronary intervention for coronary heart disease sheds light on its physiological impact. From January 2019 to December 2021, a group of 184 individuals with coronary heart disease underwent percutaneous coronary intervention at the hospital. A random number table was utilized to allocate 92 patients into both the control group and the study group. While the control group received heparin treatment, the study group was subjected to rivaroxaban treatment. The differences in cardiac function, coagulation function, inflammatory factors, and endothelial function indicators between the two groups were compared. The occurrence of cardiovascular adverse events was examined during the 3 mo follow-up period, aiming to compare outcomes between the two groups. Following treatment, the study group showed significant improvements as opposed to the control group. The left ventricular end-diastolic diameter exhibited a significant decrease (p<0.05), while the left ventricular ejection fraction showed a significant increase (p<0.05). The study group also exhibited prolonged prothrombin time and decreased levels of fibrinogen and D-dimer (p<0.05). Additionally, levels of inflammatory markers such as interleukin-6, tumor necrosis factor-alpha, C-reactive protein, transforming growth factor beta 1, and pentraxin-3 significantly decreased in the study group (p<0.05), while levels of nitric oxide and flow-mediated dilation significantly increased (p<0.05). Relative to the control group, the study group showed significantly lower levels (p<0.05) of endothelin-1 and von Willebrand factor. Furthermore, the incidence of cardiovascular adverse events was significantly lower in the study group after treatment (p<0.05). Rivaroxaban treatment can improve cardiac function and coagulation function after percutaneous coronary intervention in coronary heart disease patients, alleviate inflammatory response and endothelial dysfunction, minimize the presence of major cardiovascular complications and improve the prognosis.

Full-Text | PDF

Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report